FrancophonIA/ELRC3.0 huggingface dataset:
English: Similar exposures to cemiplimab are achieved with the doses of 350 mg every 3 weeks and 3 mg/kg every 2 weeks.
Slovenian: Z odmerkoma 350 mg na 3 tedne in 3 mg/kg na 2 tedna je bila dosežena podobna izpostavljenost cemiplimabu.
English: Fatigue has been reported following treatment with cemiplimab (see section 4.8).
Slovenian: Po zdravljenju s cemiplimabom so poročali o utrujenosti (glejte poglavje 4.8).
English: Cemiplimab should be withheld and anti-hyperglycaemics or insulin should be administered in patients with severe or life-threatening (Grade ≥ 3) hyperglycaemia.
Slovenian: Pri bolnikih s hudo ali smrtno nevarno (≥ 3. stopnja) hiperglikemijo je treba zdravljenje s cemiplimabom prekiniti in uporabiti antihiperglikemična zdravila ali insulin.
English: Immune-related hepatitis led to permanent discontinuation of cemiplimab in 5 (0.8%) of 591 patients.
Slovenian: Zaradi imunsko pogojenega hepatitisa je trajno prenehalo uporabljati cemiplimab 5 (0,8 %) od 591 bolnikov.
English: Immune-related adverse reactions can occur with cemiplimab.
Slovenian: Med uporabo cemiplimaba se lahko pojavijo imunsko pogojeni neželeni učinki.
English: • joint pain, swelling, polyarthritis and joint effusion
Slovenian: • bolečine v sklepih, oteklost sklepov, poliartritis in izliv v sklepih
English: Tel: +39 02 39394275
Slovenian: Sanofi S.p.A Tel: +39 02 39394275
English: Immune-related endocrinopathies, defined as treatment-emergent endocrinopathies with no clear alternate aetiology, have been observed in patients receiving cemiplimab (see section 4.8).
Slovenian: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojene endokrinopatije, opredeljene kot med zdravljenjem nastale endokrinopatije brez jasne alternativne etiologije (glejte poglavje 4.8).
English: Immune-related diarrhoea or colitis occurred in 7 (1.2%) of 591 patients receiving cemiplimab including 2 (0.3%) with Grade 3 immune-related diarrhoea or colitis.
Slovenian: Imunsko pogojena driska ali kolitis sta se pojavila pri 7 (1,2 %) od 591 bolnikov, ki so prejemali cemiplimab, vključno z 2 (0,3 %) bolnikoma, ki sta imela imunsko drisko ali kolitis 3. stopnje.
English: Type 1 diabetes mellitus led to permanent discontinuation of cemiplimab in 1 (0.2%) of 591 patients.
Slovenian: Sladkorna bolezen tipa 1 je povzročila trajno prenehanje uporabe cemiplimaba pri 1 (0,2 %) od 591 bolnikov.
English: Infusion-related reactions occurred in 54 (9.1%) of 591 patients treated with cemiplimab including 1 (0.2%) patient with Grade 3 infusion-related reaction.
Slovenian: Z infundiranjem povezane reakcije so se pojavile pri 54 (9,1 %) od 591 bolnikov, ki so prejemali cemiplimab, vključno z 1 (0,2 %) bolnikom z reakcijo 3. stopnje.
English: Thyroiditis
Slovenian: Tiroiditis
English: Infusion-related reaction
Slovenian: Z infundiranjem povezane reakcije
English: LIBTAYO is an anti-cancer medicine that contains the active substance cemiplimab, which is a monoclonal antibody.
Slovenian: Kaj je zdravilo LIBTAYO in za kaj ga uporabljamo Zdravilo LIBTAYO je zdravilo proti raku, ki vsebuje učinkovino cemiplimab.
English: Patients with suspected pneumonitis should be evaluated with radiographic imaging as indicated based on clinical evaluation and managed with cemiplimab treatment modifications and corticosteroids.
Slovenian: Bolnike, pri katerih obstaja sum na pnevmonitis, je treba oceniti z radiološkim slikanjem, kot je indicirano glede na klinično oceno, ter jih nadalje voditi s prilagoditvijo zdravljenja s cemiplimabom ter s kortikosteroidi (glejte poglavje 4.2).
English: No dose adjustment of LIBTAYO is recommended for patients with renal impairment.
Slovenian: Bolnikom z okvaro ledvic odmerka zdravila LIBTAYO ni treba prilagoditi.
English: Initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper
Slovenian: Začetni odmerek od 1 do 2 mg/kg/dan prednizona (ali enakovredno) in nato postopno zmanjšanje odmerka
English: • Gut problems (colitis)
Slovenian: • težave s črevesom (kolitis),
English: Immune system disorders Infusion-related reaction
Slovenian: Bolezni imunskega sistema Z infundiranjem povezane reakcije Pogosti Sjögrenov sindrom
English: Severitya
Slovenian: Izrazitosta
English: Resume LIBTAYO if hepatitis improves and remains at Grade 0 to 1 after corticosteroid taper to ≤10 mg/day prednisone or equivalent or returns to baseline AST or ALT after completion of corticosteroid taper
Slovenian: Nadaljujte uporabo zdravila LIBTAYO, če se hepatitis izboljša in ostane na 0. ali 1. stopnji po postopnem zmanjšanju odmerka kortikosteroida na ≤ 10 mg/dan prednizona ali enakovredno, ali če se AST ali ALT po dokončanem postopnem zmanjšanju odmerka kortikosteroida vrne na izhodiščno vrednost
English: Immune-related adverse reactions (see section 4.4) Immune-related pneumonitis
Slovenian: Imunsko pogojeni neželeni učinki (glejte poglavje 4.4)
English: Diarrhoea is a composite term that includes diarrhoea and colitis.
Slovenian: Driska je sestavljen izraz, ki vključuje drisko in kolitis.
English: Each vial contains 350 mg of cemiplimab in 7 ml of solution.
Slovenian: Ena viala vsebuje 350 mg cemiplimaba v 7 ml raztopine.
English: Do not shake the solution.
Slovenian: Raztopine ne stresajte.
English: No patient discontinued cemiplimab due to hypothyroidism.
Slovenian: Zaradi hipotiroidizma ni cemiplimaba prenehal uporabljati noben bolnik.
English: Vasculitis
Slovenian: Vaskulitis
English: Patients should be monitored for signs and symptoms of hypophysitis and managed with cemiplimab treatment modifications and corticosteroids (see section 4.2).
Slovenian: Bolnike je treba spremljati glede znakov in simptomov hipofizitisa in jih voditi s prilagoditvijo zdravljenja s cemiplimabom in s kortikosteroidi (glejte poglavje 4.2).
English: Resume LIBTAYO if adrenal insufficiency improves and remains at Grade 0 to 1 after corticosteroid taper to ≤10 mg/day prednisone or equivalent or is otherwise clinically stable
Slovenian: Nadaljujte uporabo zdravila LIBTAYO, če se nadledvična insuficienca izboljša in ostane na 0. ali 1. stopnji po postopnem zmanjšanju odmerka kortikosteroida na ≤ 10 mg/dan prednizona ali enakovredno ali je sicer klinično stabilna
English: Resume LIBTAYO if hypophysitis improves and remains at Grade 0 to 1 after corticosteroid taper to ≤10 mg/day prednisone or equivalent or is otherwise clinically stable
Slovenian: Nadaljujte uporabo zdravila LIBTAYO, če se hipofizitis izboljša in ostane na 0. ali 1. stopnji po postopnem zmanjšanju odmerka kortikosteroida na ≤ 10 mg/dan prednizona ali enakovredno ali je sicer klinično stabilen
English: Immune-related skin adverse reactions led to permanent discontinuation of cemiplimab in 2 (0.3%) of 591 patients.
Slovenian: Imunsko pogojeni neželeni učinki na kožo so povzročili trajno prenehanje uporabe cemiplimaba pri 2 (0,3 %) od 591 bolnikov.
English: Look out for these side effects while you are having LIBTAYO.
Slovenian: Medtem ko prejemate zdravilo LIBTAYO, bodite pozorni na te neželene učinke.
English: Tel: +40 (0) 21 317 31 36
Slovenian: Sanofi Romania SRL Tel: +40 (0) 21 317 31 36
English: Patients should be monitored for signs and symptoms of diarrhoea or colitis and managed with cemiplimab treatment modifications, anti-diarrhoeal agents, and corticosteroids (see section 4.2).
Slovenian: Bolnike je treba spremljati glede znakov in simptomov driske ali kolitisa ter jih voditi s prilagoditvijo zdravljenja s cemiplimabom, z antidiaroičnimi zdravili in kortikosteroidi (glejte poglavje 4.2).
English: Patients should be monitored for signs and symptoms of immune-related adverse reactions and managed with cemiplimab treatment modifications and corticosteroids (see section 4.2).
Slovenian: Bolnike je treba spremljati glede znakov in simptomov imunsko pogojenih neželenih učinkov in jih voditi s prilagoditvijo zdravljenja s cemiplimabom in s kortikosteroidi (glejte poglavje 4.2).
English: Uncommon General disorders and administration site conditions Fatigue k
Slovenian: Občasni Splošne težave in spremembe na mestu aplikacije Utrujenostk
English: Immune-related diarrhoea or colitis led to permanent discontinuation of cemiplimab in 1 (0.2%) of 591 patients.
Slovenian: Imunsko pogojena driska ali kolitis sta povzročila trajno prenehanje uporabe cemiplimaba pri 1 (0,2 %) od 591 bolnikov.
English: Immune-related pneumonitis, defined as requiring use of corticosteroids with no clear alternate aetiology, including fatal cases, has been observed in patients receiving cemiplimab (see section 4.8).
Slovenian: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojeni pnevmonitis, opredeljen s potrebo po uporabi kortikosteroidov in brez jasne alternativne etiologije, vključno s primeri s smrtnim izidom (glejte poglavje 4.8).
English: Severe and fatal immune-related adverse reactions have been observed with cemiplimab (see section 4.8).
Slovenian: Med uporabo cemiplimaba so opažali hude imunsko pogojene neželene učinke, tudi s smrtnim izidom (glejte poglavje 4.8).
English: Fertility
Slovenian: Artritisj
English: • eye pain, irritation, itchiness or redness; uncomfortable sensitivity to light • inflammation of the nerves causing tingling, numbness, weakness or burning pain of the arms or legs
Slovenian: • vnetje živcev, ki povzroči mravljinčenje, omrtvičenost, šibkost ali pekoče bolečine v rokah ali nogah
English: Hepatobiliary disorders Hepatitis f
Slovenian: Bolezni jeter, žolčnika in žolčevodov Hepatitisf
English: Immune-related nephritis led to permanent discontinuation of cemiplimab in 1 (0.2%) of 591 patients.
Slovenian: Imunsko pogojeni nefritis je povzročil trajno prenehanje uporabe cemiplimaba pri 1 (0,2 %) od 591 bolnikov.
English: Immune-related skin adverse reactions
Slovenian: Imunsko pogojeni neželeni učinki na kožo
English: Immune-related hepatitis, defined as requiring use of corticosteroids with no clear alternate aetiology, including fatal cases, has been observed in patients receiving cemiplimab (see section 4.8).
Slovenian: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojeni hepatitis, opredeljen s potrebo po uporabi kortikosteroidov in brez jasne alternativne etiologije, vključno s primeri s smrtnim izidom (glejte poglavje 4.8).
English: Resume LIBTAYO if skin reaction or other immune-related adverse reaction improves and remains at Grade 0 to 1 after corticosteroid taper to ≤10 mg/day prednisone or equivalent
Slovenian: Nadaljujte uporabo zdravila LIBTAYO, če se kožna reakcija ali drugi imunsko pogojeni neželeni učinki izboljšajo in ostanejo na 0. ali 1. stopnji po postopnem zmanjšanju odmerka kortikosteroida na ≤ 10 mg/dan prednizona ali enakovredno
English: Thyroid disorders (Hypothyroidism/Hyperthyroidism) Immune-related thyroid disorders have been observed in patients receiving cemiplimab.
Slovenian: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojene ščitnične motnje.
English: Patients should be monitored for signs and symptoms of adrenal insufficiency during and after treatment and managed with cemiplimab treatment modifications and corticosteroids (see section 4.2).
Slovenian: Bolnike je treba med zdravljenjem in po njem spremljati glede znakov in simptomov nadledvične insuficience in jih voditi s prilagoditvijo zdravljenja s cemiplimabom in s kortikosteroidi (glejte poglavje 4.2).
English: shaking or fever, itching or rash, flushing or swollen face, being short of breath or wheezing, feeling dizzy or feel like passing out and back or neck pain.
Slovenian: • Reakcije povezane z infundiranjem (včasih so lahko hude ali življenjsko nevarne), na primer mrzlico, tresenje ali zvišano telesno temperaturo, srbenje ali izpuščaj, zardevanje ali oteklost obraza, kratko sapo ali piskajoče dihanje, omotičnost ali občutek omedlevice ter bolečine v hrbtu ali vratu.
English: b.
Slovenian: f.
English: Pericarditis
Slovenian: Perikarditis
English: Or
Slovenian: ali
English: One ml of concentrate contains 50 mg of cemiplimab.
Slovenian: KAKOVOSTNA IN KOLIČINSKA SESTAVA En mililiter koncentrata vsebuje 50 mg cemiplimaba.
English: LIBTAYO.
Slovenian: ZMN
English: No patient discontinued cemiplimab due to adrenal insufficiency.
Slovenian: Zaradi nadledvične insuficience ni cemiplimaba prenehal uporabljati noben bolnik.
English: LIBTAYO has not been studied in patients with moderate or severe hepatic impairment.
Slovenian: Pri bolnikih z zmerno ali hudo okvaro jeter zdravilo LIBTAYO ni raziskano.
English: Resume LIBTAYO if pneumonitis improves and remains at Grade 0 to 1 after corticosteroid taper to ≤10 mg/day prednisone or equivalent
Slovenian: Nadaljujte uporabo zdravila LIBTAYO, če se pnevmonitis izboljša in ostane na 0. ali 1. stopnji po postopnem zmanjšanju odmerka kortikosteroida na ≤ 10 mg/dan prednizona ali enakovredno
English: LIBTAYO 350 mg sterile concentrate cemiplimab
Slovenian: IME ZDRAVILA IN POT(I) UPORABE LIBTAYO 350 mg sterilen koncentrat cemiplimab i.v.
English: No dose adjustment is recommended for patients with mild hepatic impairment.
Slovenian: Bolnikom z okvaro jeter odmerka ni treba prilagoditi.
English: Resume LIBTAYO if other immune-related adverse reaction improves and remains at Grade 0 to 1 after corticosteroid taper to ≤10 mg/day prednisone or equivalent
Slovenian: Nadaljujte uporabo zdravila LIBTAYO, če se drugi imunsko pogojeni neželeni učinki izboljšajo in ostanejo na 0. ali 1. stopnji po postopnem zmanjšanju odmerka kortikosteroida na ≤ 10 mg/dan prednizona ali enakovredno
English: ICR
Slovenian: NCP
English: Nephritis
Slovenian: Nefritis
English: • inflammation of the liver
Slovenian: • vnetje ledvic
English: Immune-related diarrhoea or colitis, defined as requiring use of corticosteroids with no clear alternate aetiology, has been observed in patients receiving cemiplimab (see section 4.8).
Slovenian: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojeno drisko ali kolitis, opredeljena s potrebo po uporabi kortikosteroidov in brez jasne alternativne etiologije (glejte poglavje 4.8).
English: Resume LIBTAYO if skin reaction improves and remains at Grade 0 to 1 after corticosteroid taper to ≤10 mg/day prednisone or equivalent
Slovenian: Nadaljujte uporabo zdravila LIBTAYO, če se kožna reakcija izboljša in ostane na 0. ali 1. stopnji po postopnem zmanjšanju odmerka kortikosteroida na ≤ 10 mg/dan prednizona ali enakovredno
English: Gastrointestinal disorders Diarrhoea e
Slovenian: Srčne bolezni Miokarditisd
English: Polysorbate 80
Slovenian: L-prolin polisorbat 80 voda za injekcije
English: Progression free survival (PFS)
Slovenian: Preživetje brez napredovanja bolezni (PFS)a, c 6 mesecev 12 mesecev
English: Immune-related nephritis, defined as requiring use of corticosteroids with no clear alternate aetiology, has been observed in patients receiving cemiplimab (see section 4.8).
Slovenian: Pri bolnikih, ki so prejemali cemiplimab, so opažali imunsko pogojeni nefritis, opredeljen s potrebo po uporabi kortikosteroidov in brez jasne alternativne etiologije (glejte poglavje 4.8).
English: ORR
Slovenian: Hrvatska
English: • Infusion-related reactions
Slovenian: • z infundiranjem povezane reakcije,
English: Resume LIBTAYO if nephritis improves and remains at Grade 0 to 1 after corticosteroid taper to ≤10 mg/day prednisone or equivalent
Slovenian: Nadaljujte uporabo zdravila LIBTAYO, če se nefritis izboljša in ostane na 0. ali 1. stopnji po postopnem zmanjšanju odmerka kortikosteroida na ≤ 10 mg/dan prednizona ali enakovredno
English: Cardiac disorders Myocarditis d
Slovenian: c Vključuje avtoimunski miokarditis in miokarditis.
English: Resume LIBTAYO when diabetes mellitus returns to Grade 0 to 1 or is otherwise clinically stable
Slovenian: Uvedite zdravljenje z antihiperglikemičnimi zdravili, kot je klinično indicirano Nadaljujte uporabo zdravila LIBTAYO, ko se sladkorna bolezen vrne na 0. ali 1. stopnjo ali je sicer klinično stabilna
English: Resume LIBTAYO when hypothyroidism returns to Grade 0 to 1 or is otherwise clinically stable
Slovenian: Uvedite nadomeščanje ščitničnih hormonov, kot je klinično indicirano Nadaljujte uporabo zdravila LIBTAYO, ko se hipotiroidizem vrne na 0. ali 1. stopnjo ali je sicer klinično stabilen
English: Immediate packaging
Slovenian: Pot uporabe Stična ovojnina Velikost pakiranja
English: 1.33 ml (150 mg/ml)
Slovenian: 200 mg Koncentrat za raztopino za infundiranje intravenska uporaba viala (steklena) 1,33 ml (150 mg/ml)
English: Intravenous use vial (glass)
Slovenian: Pot uporabe Stična ovojnina
English: List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states
Slovenian: DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V
English: United Kingdom Teva United Kingdom Limted
Slovenian: Velika Britanija Teva United Kingdom Limted
English: United Kingdom Ennogen Limited 78 York Street
Slovenian: Velika Britanija Ennogen Limited 78 York Street
English: Empreendimento Lagoas Park
Slovenian: Lagoas Park
English: Luxembourg Hexal AG Industriestr.
Slovenian: Luksemburg Hexal AG Industriestr.
English: United Kingdom Actavis UK Limited Whiddon Valley
Slovenian: Velika Britanija Actavis UK Limited Whiddon Valley
English: Luxembourg Eurogenerics s.a. Heizel Esplanade B22
Slovenian: Luksemburg Eurogenerics s.a. Heizel Esplanade B22
English: United Kingdom Amdipharm plc Regency House
Slovenian: Velika Britanija Amdipharm plc Regency House
English: Kampenringweg 45 D-E 2803 PE GOUDA The Netherlands
Slovenian: Kampenringweg 45 D-E 2803 PE GOUDA
English: 1000 Ljubljana
Slovenian: 1000 Ljubljana Slovenia
English: Finland sanofi-aventis Oy Huopalahdentie 24 00350 Helsinki Finland
Slovenian: Finska sanofi-aventis Oy Huopalahdentie 24 00350 Helsinki Finland
English: Luxembourg Nycomed Belgium s.a. 615, chaussee de Gand B-1080 Bruxelles
Slovenian: Luksemburg Nycomed Belgium s.a. 615, chaussee de Gand B-1080 Bruxelles
English: 82102 Bratislava
Slovenian: 82102 Bratislava Slovakia
English: Labesfal - Laboratórios Almiro, S.A.
Slovenian: Portugalska Labesfal - Laboratórios Almiro, S.A.
English: United Kingdom Accord Healthcare Ltd Sage House
Slovenian: Velika Britanija Accord Healthcare Ltd Sage House
English: Laboratório MedinfarProdutos Farmacêuticos, S.A. l Ribeiro de Pavia, 1 - 1ºVenda Nova 2700-547 Amadora Portugal
Slovenian: Portugalska Laboratório MedinfarProdutos Farmacêuticos, S.A. l Ribeiro de Pavia, 11º - Venda Nova 2700547 Amadora Portugal
English: Luxembourg Sanofi-Aventis Belgium Culliganlaan 1 C
Slovenian: Luksemburg Sanofi-Aventis Belgium Culliganlaan 1 C
English: United Kingdom Chelonia Healthcare Limited
Slovenian: Velika Britanija Chelonia Healthcare Limited
English: Luxembourg Ratiopharm GMBH Arzneimittel
Slovenian: Luksemburg Ratiopharm GMBH Arzneimittel
English: United Kingdom Mercury Pharma International Limited 4045 Kingswood Raod City West Business Park County Dublin
Slovenian: Velika Britanija Mercury Pharma International Limited 4045 Kingswood Raod City West Business Park County Dublin
English: Radlická 3185/1c
Slovenian: Radlická 3185/1c 150 00 Prague Czech Republic
English: 83-200 Starogard Gdański Poland
Slovenian: 83-200 Starogard
English: Laboratório MedinfarProdutos Farmacêuticos, S.A.
Slovenian: Portugalska Laboratório MedinfarProdutos Farmacêuticos, S.A.
English: Zona Industrial do Lagedo 3465-157 Santiago de Besteiros
Slovenian: 3465-157 Santiago de Besteiros
English: 176 74 Kalithea - Athens Greece
Slovenian: 176 74 KalitheaAthens
English: Capsule, soft
Slovenian: kapsula, mehka
English: S.C. TERAPIA S.A. Str. Fabricii nr. 124 Cluj - Napoca 400632 România
Slovenian: Str. Fabricii nr. 124 Cluj - Napoca 400632 România
English: Meda Pharma France 25, boulevard de l'Amiral Bruix
Slovenian: Meda Pharma France 25, boulevard de l'Amiral Bruix 75016 Paris France
English: Netherlands
Slovenian: The Netherlands
English: Syrup
Slovenian: sirup
English: Slovak Republic TEVA Pharmaceuticals Slovakia s.r.o.
Slovenian: TEVA Pharmaceuticals Slovakia s.r.o.
English: Alexandriei, nr 145 A B07-Bragadiru, jud Ilfov România
Slovenian: B07-Bragadiru, jud Ilfov România
English: Abbott Arzneimittel GmbH Freundallee 9A 30173 Hannover Germany
Slovenian: Freundallee 9A 30173 Hannover Germany
English: Luxembourg Dolorgiet Gmbh&Co Otto-von-Guericke-Str. 1
Slovenian: Luksemburg Dolorgiet Gmbh&Co Otto-von-Guericke-Str.
English: Sanofi-Aventis Netherlands B.V.
Slovenian: Nizozemska Sanofi-Aventis Netherlands B.V.
English: 1 - 1 - Venda Nova 2700-547 Amadora Portugal
Slovenian: 2700-547 Amadora
English: ARENA GROUP S.A Str. Stefan Mihaileanu, nr.31 sector 2; Bucuresti 024022 România
Slovenian: S.C. ARENA GROUP S.A Str. Stefan Mihaileanu, nr.31 sector 2; Bucuresti
English: Hampden Park, Eastbourne East Sussex BN22 9AG United Kingdom
Slovenian: East Sussex BN22 9AG United Kingdom
English: United Kingdom Hameln Pharmaceuticals Limited
Slovenian: Velika Britanija Hameln Pharmaceuticals Limited
English: Miles Gray Road, Basildon Essex SS14 3AF
Slovenian: Miles Gray Road, Basildon
English: Czech Republic Teva Pharmaceuticals CR, s.r.o.
Slovenian: Teva Pharmaceuticals CR, s.r.o.
English: Primperan for adults suppository 20mg
Slovenian: Primperan for adults suppository 20mg svečka rektalna uporaba
English: MCP-ratiopharm SF 50 mg/10 ml Konzentrat zur Herstellung einer Infusionslösung
Slovenian: MCP-ratiopharm SF 50 mg/10 ml Konzentrat zur Herstellung einer Infusionslösung koncentrat za raztopino za infundiranje intravenska uporaba
English: PRIMPERAN NOURRISSONS ET ENFANTS 2,6 mg/ml, solution buvable
Slovenian: PRIMPERAN NOURRISSONS ET ENFANTS 2,6 mg/ml, solution buvable peroralne kapljice, raztopina
English: Solution for injection Intravenous use
Slovenian: raztopina za injiciranje intravenska uporaba
English: 01445 Radebeul
Slovenian: 01445 Radebeul Germany
English: DIGESTIVO S.PELLEGRINO 5mg
Slovenian: DIGESTIVO S.PELLEGRINO 5 mg šumeča zrnca
English: Zakłady Farmaceutyczne Polpharma SA ul.
Slovenian: Farmaceutyczne Polpharma SA
English: 1526 Ljubljana
Slovenian: Verovškova 57 1526 Ljubljana Slovenia
English: Reglan 1 mg/1 ml peroralna raztopina
Slovenian: Reglan 1 mg/1 ml peroralna raztopina peroralna raztopina peroralna uporaba
English: Paspertin 50 mg - Konzentrat zur Infusionsbereitung
Slovenian: Paspertin 50 mgKonzentrat zur Infusionsbereitung koncentrat za raztopino za infundiranje intravenska uporaba
English: MCP Sandoz 4mg/ml Tropfen zum Einnehmen, Lösung
Slovenian: MCP Sandoz 4mg/ml Tropfen zum Einnehmen, Lösung peroralna raztopina peroralna uporaba
English: Paspertin - Filmtabletten
Slovenian: Paspertin Filmtabletten filmsko obložena tableta
English: Primperan drank, drank 1 mg/ml
Slovenian: Primperan drank, drank 1 mg/ml peroralna raztopina peroralna uporaba
English: MCP AbZ 5 mg/ml Tropfen 5.91mg/ml
Slovenian: MCP AbZ 5 mg/ml Tropfen 5,91 mg/ml peroralna raztopina peroralna uporaba
English: ANAUSIN METOCLOPRAMIDE 15 mg, comprimé à libération prolongée
Slovenian: METOCLOPRAMIDE 15 mg, comprimé à libération prolongée tableta s podaljšanim sproščanjem
English: Hexal Pharma GmbH Stella-Klein-Löw-Weg 17 1020 Wien
Slovenian: Hexal Pharma GmbH Stella-Klein-Löw-Weg
English: CSC Pharmaceuticals Ltd. 10 Assen Yordanov str. Sofia
Slovenian: 10 Assen Yordanov str. Sofia
English: D-90449 Nürnberg
Slovenian: Südwestpark 50 D-90449 Nürnberg
English: Slovak Republic Sandoz Pharmaceuticals d.d.
Slovenian: Sandoz Pharmaceuticals d.d.
English: MCP STADA 4mg/1ml Tropfen zum Einnehmen, Lösung
Slovenian: MCP STADA 4mg/1ml Tropfen zum Einnehmen, Lösung peroralna raztopina peroralna uporaba
English: MCP Hexal Tropfen
Slovenian: MCP Hexal Tropfen peroralna kapljice
English: CHLORHYDRATE DE METOCLOPRAMIDE RICHARD 1 mg/ml, solution buvable
Slovenian: CHLORHYDRATE DE METOCLOPRAMIDE RICHARD 1 mg/ml, solution buvable peroralna raztopina peroralna uporaba
English: Metoclopramide Hydrochloride 5mg/5ml Oral Solution
Slovenian: Metoclopramide Hydrochloride 5mg/5ml Oral Solution peroralna raztopina peroralna uporaba
English: Sanofi Aventis Cyprus ltd Charalambou Mouskou 14 2015 Strovolos Nicosia Cyprus
Slovenian: Sanofi Aventis Cyprus ltd
English: Station Close, Potters Bar Hertfordshire EN6 1TL
Slovenian: Hertfordshire EN6 1TL United Kingdom
English: D-90449 Nürnberg Germany
Slovenian: Südwestpark 50 D-90449 Nürnberg Germany